163 related articles for article (PubMed ID: 38193937)
1. Quality of life following treatment with intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer.
Cossyleon R; Robinson K; Delfino K; Robbins KT; Rao K
Support Care Cancer; 2024 Jan; 32(2):93. PubMed ID: 38193937
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer.
Rao K; Kalapurakal S; Chalasani P; Robinson K; Malone J; Clausen C; Ronen O; Dhiwakar M; Shevlin B; Robbins KT
Cancer Chemother Pharmacol; 2013 Sep; 72(3):545-52. PubMed ID: 23884559
[TBL] [Abstract][Full Text] [Related]
3. Racial disparity in oncologic and quality-of-life outcomes in patients with locally advanced head and neck squamous cell carcinomas enrolled in a randomized phase 2 trial.
Guerriero MK; Redman MW; Baker KK; Martins RG; Eaton K; Chow LQ; Santana-Davila R; Baik C; Goulart BH; Lee S; Rodriguez CP
Cancer; 2018 Jul; 124(13):2841-2849. PubMed ID: 29669181
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: a GICOR phase I trial.
Arias de la Vega F; Contreras J; de Las Heras M; de la Torre A; Arrazubi V; Herruzo I; Prieto I; García-Saenz JA; Romero J; Calvo FA;
Ann Oncol; 2012 Apr; 23(4):1005-9. PubMed ID: 21778302
[TBL] [Abstract][Full Text] [Related]
5. Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone - Additional data from a phase 3 trial.
Menon N; Patil V; Noronha V; Joshi A; Bhattacharjee A; Satam BJ; Mathrudev V; Ghosh Laskar S; Prabhash K
Oral Oncol; 2021 Nov; 122():105517. PubMed ID: 34560383
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of erlotinib and docetaxel with concurrent intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinoma.
Yao M; Woods C; Lavertu P; Fu P; Gibson M; Rezaee R; Zender C; Wasman J; Sharma N; Machtay M; Savvides P
Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E1770-6. PubMed ID: 26918562
[TBL] [Abstract][Full Text] [Related]
7. Late toxicity after radical treatment for locally advanced head and neck cancer.
Taberna M; Rullan AJ; Hierro C; Navarro V; Vázquez S; Lozano A; Vilajosana E; Maños M; Marí A; Viñals J; Mesía R
Oral Oncol; 2015 Aug; 51(8):795-9. PubMed ID: 26051499
[TBL] [Abstract][Full Text] [Related]
8. Acute and chronic changes in swallowing and quality of life following intraarterial chemoradiation for organ preservation in patients with advanced head and neck cancer.
Murry T; Madasu R; Martin A; Robbins KT
Head Neck; 1998 Jan; 20(1):31-7. PubMed ID: 9464950
[TBL] [Abstract][Full Text] [Related]
9. Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once-a-week versus once-every-3-weeks cisplatin.
Menon NS; Noronha V; Patil VM; Joshi A; Bhattacharjee A; Kalra D; Laskar SG; Mathrudev V; Nawale K; Bhelekar AS; Prabhash K
Cancer Med; 2022 Nov; 11(21):3939-3948. PubMed ID: 35343648
[TBL] [Abstract][Full Text] [Related]
10. Five-year quality of life results of the randomized clinical phase III (RADPLAT) trial, comparing concomitant intra-arterial versus intravenous chemoradiotherapy in locally advanced head and neck cancer.
Ackerstaff AH; Rasch CR; Balm AJ; de Boer JP; Wiggenraad R; Rietveld DH; Gregor RT; Kröger R; Hauptmann M; Vincent A; Hilgers FJ
Head Neck; 2012 Jul; 34(7):974-80. PubMed ID: 21818820
[TBL] [Abstract][Full Text] [Related]
11. Feasibility and toxicity of concurrent chemoradiation for elderly patients with head and neck cancer.
Daly ME; Lau DH; Farwell DG; Luu Q; Donald PJ; Chen AM
Am J Otolaryngol; 2013; 34(6):631-5. PubMed ID: 23954137
[TBL] [Abstract][Full Text] [Related]
12. Late follow-up of the randomized radiation and concomitant high-dose intra-arterial or intravenous cisplatin (RADPLAT) trial for advanced head and neck cancer.
Heukelom J; Lopez-Yurda M; Balm AJ; Wijers OB; Buter J; Gregor T; Wiggenraad R; de Boer JP; Tan IB; Verheij M; Sonke JJ; Rasch CR
Head Neck; 2016 Apr; 38 Suppl 1():E488-93. PubMed ID: 25728984
[TBL] [Abstract][Full Text] [Related]
13. Promising long-term results with attenuated adverse effects by methotrexate-containing sequential chemoradiation therapy in locally advanced head and neck squamous cell carcinoma.
Tsai TL; Chu PY; Tai SK; Wang YF; Yang MH; Wang LW; Lirng JF; Chang SY
Jpn J Clin Oncol; 2011 Oct; 41(10):1182-93. PubMed ID: 21862506
[TBL] [Abstract][Full Text] [Related]
14. High-dose intra-arterial cisplatin and concurrent hyperfractionated radiation therapy in patients with locally advanced primary squamous cell carcinoma of the head and neck: report of a phase II study.
Regine WF; Valentino J; John W; Storey G; Sloan D; Kenady D; Patel P; Pulmano C; Arnold SM; Mohiuddin M
Head Neck; 2000 Sep; 22(6):543-9. PubMed ID: 10941154
[TBL] [Abstract][Full Text] [Related]
15. Quality of life following chemoradiation and postoperative radiation for locally advanced head and neck cancer.
Nguyen NP; Vos P; Karlsson U; Nguyen P; Dutta S; Lemanski C; Ludin A; Rose S; Nguyen LM; Ward H; Huang S; Sallah S
ORL J Otorhinolaryngol Relat Spec; 2007; 69(5):271-6. PubMed ID: 17565229
[TBL] [Abstract][Full Text] [Related]
16. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
17. Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129.
Xiao C; Zhang Q; Nguyen-Tân PF; List M; Weber RS; Ang KK; Rosenthal D; Filion EJ; Kim H; Silverman C; Raben A; Galloway T; Fortin A; Gore E; Winquist E; Jones CU; Robinson W; Raben D; Le QT; Bruner D
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):667-677. PubMed ID: 27727063
[TBL] [Abstract][Full Text] [Related]
18. Quality-of-life assessment after supradose selective intra-arterial cisplatin and concomitant radiation (RADPLAT) for inoperable stage IV head and neck squamous cell carcinoma.
Ackerstaff AH; Tan IB; Rasch CR; Balm AJ; Keus RB; Schornagel JH; Hilgers FJ
Arch Otolaryngol Head Neck Surg; 2002 Oct; 128(10):1185-90. PubMed ID: 12365891
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck.
Gilbert J; Rudek MA; Higgins MJ; Zhao M; Bienvenu S; Tsottles N; Chaudhry MA; Wahl R; Forastiere A; Gillison M
Clin Cancer Res; 2012 Mar; 18(6):1735-42. PubMed ID: 22271880
[TBL] [Abstract][Full Text] [Related]
20. Quality of life among long-term survivors of head and neck cancer treated by intensity-modulated radiotherapy.
Chen AM; Daly ME; Farwell DG; Vazquez E; Courquin J; Lau DH; Purdy JA
JAMA Otolaryngol Head Neck Surg; 2014 Feb; 140(2):129-33. PubMed ID: 24337483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
